177Lu-DOTATATE

DRUG11 trials

Sponsors

Ebrahim S Delpassand, Jules Bordet Institute, IRCCS San Raffaele, Fundación de investigación HM, Memorial Sloan Kettering Cancer Center

Conditions

Advanced CancerGastro-intestinal Neuroendocrine TumorsLiver-Dominant Metastatic Pancreatic Neuroendocrine TumorsMetastatic Pancreatic Neuroendocrine TumorNeuroblastomaNeuroblastoma RecurrentNeuroendocrine (NE) TumorsNeuroendocrine Carcinomas (NEC)

Early Phase 1

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Active, not recruitingNCT04544098

Memorial Sloan Kettering Cancer CenterLiver-Dominant Metastatic Pancreatic Neuroendocrine Tumors, Neuroendocrine Tumors

Start: 2020-09-02End: 2026-09-30Updated: 2025-05-02

Phase 1

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

RecruitingNCT06122610

University of Wisconsin, MadisonNeuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor

Start: 2025-03-07End: 2026-06-01Target: 10Updated: 2026-03-19

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

RecruitingNCT06663072

University of ChicagoMetastatic Pancreatic Neuroendocrine Tumor

Start: 2024-12-13End: 2026-11-30Target: 25Updated: 2026-01-09

Phase 2

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

CompletedNCT01237457

Ebrahim S DelpassandNeuroendocrine Tumors

Start: 2010-10-27End: 2017-07-25Updated: 2023-03-20

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

CompletedNCT04385992

IRCCS San RaffaeleNeuroendocrine Tumors

Start: 2020-03-09End: 2023-06-26Updated: 2023-06-27

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Fundación de investigación HMNeuroendocrine Carcinomas (NEC), Neuroendocrine Tumours (NET)

Start: 2020-06-29End: 2024-09-30Target: 30Updated: 2022-08-02

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

RecruitingNCT04903899

Jakob StenmanNeuroblastoma, Neuroblastoma Recurrent

Start: 2021-05-19End: 2031-05-20Target: 24Updated: 2025-02-11

177Lu-DOTATATE for Recurrent Meningioma

RecruitingNCT06326190

European Organisation for Research and Treatment of Cancer - EORTCRecurrent Meningioma

Start: 2025-03-10End: 2028-12-22Target: 136Updated: 2025-09-16

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

TerminatedNCT07012330

Erasmus Medical CenterNeuroendocrine (NE) Tumors

Start: 2007-03-01End: 2015-12-31Updated: 2025-06-10

Phase 3

Randomized Phase III of PRRT Versus Interferon

WithdrawnNCT01860742

Jules Bordet InstituteGastro-intestinal Neuroendocrine Tumors

Start: 2014-12-31End: 2016-10-31Updated: 2016-04-05

Unknown Phase

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

RecruitingNCT06389097

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAdvanced Cancer, Prostate Cancer

Start: 2025-02-03End: 2029-08-01Target: 80Updated: 2026-03-30

Related Papers

Phase I study of fulvestrant in combination with <sup>177</sup> Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.

Journal of Clinical Oncology2026-01-10

[<sup>177</sup>Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial.

2026-01-021 citations

[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial

Universität Zürich, ZORA2026-01-01

TIP-01. [177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial

Neuro-Oncology2025-11-01

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE

EJNMMI Physics2022-03-2813 citations

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Frontiers in Pediatrics2022-03-1026 citations

Treatment of high grade metastatic neuroendocrine tumor (mNET) with peptide receptor radionuclide therapy (PRRT): Retrospective analysis in a single referral center.

Journal of Clinical Oncology2015-05-206 citations